Business
RenovaCare, Inc. Enters R&D Partnership with World Leading Charité
RenovaCare, Inc. Enters R&D Partnership with World Leading Charité.
About this update from Renovacare, Inc.
[{"type":"text","content":"\n \n RenovaCare, Inc. (OTCQB:RCAR), today announced a partnership to validate \n the science behind its groundbreaking technology for treatments of \n wounds, burns and other skin defects. The company’s research partner is \n Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a \n translational research center at Charité - Universitätsmedizin Berlin, \n one of the world’s largest university hospitals.\n \n\nThis Smart News Release features multimedia. View the full release here: \nhttp://www.businesswire.com/news/home/20151117005439/en/\n\n \n \n RenovaCare System uses the patient's own stem cells to regenerate skin for burns and wounds. (Photo: Business Wire) \n\n\n \n The BCRT focuses on enhancing endogenous regeneration by cells, \n biomaterials, and factors, which can be used to develop and implement \n innovative therapies and products. RenovaCare, Inc. is the developer of \n the patented CellMist™ and SkinGun™ technologies for isolating and \n spraying a patient’s own stem cells onto burns and wounds for rapid \n self-healing.\n \n \n “This collaboration with a globally-renowned institution is a huge step \n forward for RenovaCare as we set out to achieve third party validation \n of the science behind the promise of our CellMist™ and SkinGun™ \n technologies,” said Thomas Bold, President and CEO of RenovaCare, Inc. \n “We are honored to be working with such committed researchers known for \n partnering with innovative, world-class companies whose mission is to \n make peoples’ lives better.”\n \n \n “We are very excited to be working with RenovaCare to advance the \n treatment of burns, and this project underscores the new treatments for \n severely burned patients and those with myriad skin conditions,” said \n Dr. Katrin Zeilinger, Project Leader for BCRT. “We plan to assess all \n aspects of the company’s technology as it is related to the tissue’s \n wound-healing function and the characteristics of the treated site.”\n \n \n The objective of today’s announced research partnership is to evaluate \n protocols, methods, and outcomes related to the use of the RenovaCare \n proprietary SkinGun™. This includes better understanding the ability of \n delicate stem cells to survive ...